The pro-inflammatory response to interleukin 6 (IL6) trans-signalling in atherosclerosis is driven by the IL6 and soluble IL6 receptor (sIL6R) binary complex. The binary IL6:sIL6R complex is inactivated by sgp130 through the formation of the ternary IL6:sIL6R:sgp130 complex. The aim of this study was to investigate if IL6 trans-signalling, estimated by a ratio between the binary and ternary complexes, associates with the risk of future cardiovascular events (CVE) in a Swedish cohort of 60-year-old men and women (n = 4232). 
Introduction
Interleukin 6 (IL6) is a pleiotropic cytokine able to exert divergent effects on cell metabolism depending on whether binding to the membrane bound IL6 receptor (IL6R) or to the circulating soluble IL6R (sIL6R). Both the IL6R and sIL6R need the ubiquitously expressed membrane bound co-receptor, gp130, to transduce the IL6 signal. 1, 2 IL6 binding to the IL6R (also known as classic signalling) has homeostatic functions. It regulates cell regeneration, haematopoiesis and synthesis and release of C-reactive protein (CRP), and other acute phase proteins. The classical IL6 signalling is limited to the few cell types expressing the IL6R: hepatocytes, megakaryocytes, and lymphoid cells.
On the other hand, IL6 binding to the sIL6R (also known as transsignalling) promotes a pro-inflammatory response. 3 The circulating sIL6R enables IL6 trans-signalling to act systemically: once formed in the circulation the IL6:sIL6R (binary) complex is able to bind gp130 on every cell ( Figure 1A , red arrows). IL6 trans-signalling is tightly regulated; a soluble isoform of gp130 (sgp130) binds with high affinity the binary complex creating the IL6:sIL6R:sgp130 (ternary) complex. The ternary complex is unable to bind and activate gp130, thus neutralizing the agonistic binary IL6:sIL6R complex ( Figure 1A , black arrows). Of importance, sgp130 leaves unaffected classical IL6 signalling, i.e. the IL6 functions mediated by IL6R. 4 The Cantos trial recently showed promising results in targeting IL1b and thus affecting the downstream IL6 classical and trans-signalling pathways with a reduced recurrence of cardiovascular events (CVE) in patients with previous myocardial infarction (MI) and high-sensitivity CRP > _2 mg/L. 5 .
The IL6 trans-signalling contributes to the inflammatory response in atherosclerosis 3 and antagonism of IL6 trans-signalling with a recombinant form of sgp130 has in fact been shown to be associated with a reduced progression and even regression of atherosclerotic lesions in an experimental animal model of atherosclerosis. 6 Moreover, data from observational studies suggest that high circulating levels of IL6, 7 sIL6R, 8, 9 and sgp130 10 are associated with an increased risk of CVE and an unfavourable cardiovascular (CV) risk profile. Neither of the soluble receptors nor IL6 can however function without each other. Thus, to estimate the effect of IL6 trans-signalling on the risk of CVE, we tried to assess the concentration of the two functional entities; the active binary and inactive ternary complex and analyse their association to the risk of future CVE. The aim of this study was to analyse the association between IL6 trans-signalling and the risk of future CVE in a large prospective CV cohort of 60-year-old men and women from Stockholm. To this extent, we have derived the concentration of the circulating binary and ternary complexes from the circulating levels of IL6 and its soluble receptors and analysed the association of the binary and ternary complex with future CVE.
Methods

Study population
The cohort of 60-year-old men and women from Stockholm is a prospective CV study fully described elsewhere. 11 Briefly, every third man and woman living in the Stockholm County and turning 60 between 1 July 1997 and 30 June 1998 was randomly selected from the Swedish population register and invited to participate in a CV health screening study. A total of 4232 subjects (2039 men and 2193 women) replied positively (response rate 78%) and were included in the study. Study participants filled in a comprehensive questionnaire on their social status, education, lifestyle habits, previous and current diseases and medications; underwent a physical examination and had an electrocardiogram recorded. At baseline, whole blood, serum, and plasma were collected Figure 1 Schematic representation of IL6 trans-signalling and association of the binary/ternary complex ratio with the risk of CVE. (A) Once released in the circulation, the sIL6R binds IL6 and forms the binary IL6:sIL6R complex that activates the ubiquitously expressed membrane bound co-receptor gp130 (red arrows). This signalling system is called trans-signalling and transduces the pro-inflammatory and pro-atherogenic signals of IL6. Alternatively, the binary IL6:sIL6R complex can bind with high affinity a soluble isoform of the gp130 receptor (sgp130). The ternary IL6:sIL6R:sgp130 complex is unable to bind gp130, and thus the binary complex is neutralized (black arrows). The fine tuning of this system relies on the balance between active and inactive trans-signalling driven by the binary and ternary complex, respectively. (B) The graph shows the association of the binary/ternary complex ratio with the risk of CVE estimated by Cox regression, expressed as HR, after adjustment for the common CV risk factors. The binary/ternary complex ratio values and the corresponding percentiles are denoted on the x-axis at the bottom and at the top of the graph, respectively. When compared with the reference group (40-60th percentile), higher binary/ternary complex ratio (relative excess of the active binary complex) were associated with an increased risk of CVE, while lower binary/ternary complex ratio (relative excess of the inactive ternary complex) were associated with a reduced risk of CVE. Details of the association analysis are presented in Table 2 and Supplementary material online, Table S2 . Figure 2 Graphical representation of the association of IL6, sIL6R, and sgp130 with the risk of CVE modelled using natural cubic splines. The graph shows the association of increasing serum concentrations of IL6 (pg/mL) (A), sIL6R (ng/mL) (B), and sgp130 (ng/mL) (C) with the risk of CVE estimated by Cox regression and expressed as HR using natural cubic splines. Graphs are modelled with the independent variable as a continuous variable in the crude model. in the morning with the subjects fasting, frozen (-80 C) and stored until analyses. For the purpose of the present study, 3624 study participants were included in the analysis. Supplementary material online, Figure S1 illustrates the inclusion and exclusion criteria applied in this study.
Ethics
The cohort of 60-year-old men and women from Stockholm was designed and conducted in accordance with the Helsinki Declaration. Eligible study participants were randomly selected from the Swedish population registry. All selected study participants received a letter with an invitation to participate in the study together with a complete description of the study. The invitation letter clearly stated that participation was voluntary and that a physician was going to interpret the results of the health screening and give appropriate medical advice if and when needed. All study participants who agreed to participate were asked to contact a booking central to inform whether he or she would like to participate or not. At the time the study was initiated written consent forms were not in current use in Sweden. The nurses working at the booking central documented each reply, so that those who agreed to participate received the questionnaire and an appointment for the health screening and those who were not willing to participate were withdrawn from the list of eligible participants.
The consent procedure and the study were approved in 1996 by the Regional Ethics Review Board at Karolinska Institutet, Stockholm, Sweden in the original application (reference number 96-398) and in more recent renewed applications for continued research on the cohort (reference numbers 99-306, 03-100 and 03-115, 16/205-31/2).
Outcome ascertainment
The study participants' personal identification numbers were linked yearly to the mandatory national Swedish registries, the Hospital Discharge Register, and National Cause of Death Register, to extract diagnoses. The primary endpoint was a composite of first time incident fatal and non-fatal CVE. Cases were ascertained using the following diagnosis codes according to the International Classification of Diseases 10th revision: MI (I21); coronary heart disease (CHD) (I20 and I25); sudden cardiac death (I46); and ischaemic stroke (I63). Definition of fatal CVE was sudden cardiac death or death where MI or ischaemic stroke was the underlying diagnosis. Only main diagnoses were recorded (100% follow up) until 31 December 2014. After applying the exclusion criteria, 546 incident cases of CVE were recorded (Supplementary material online, Figure S1 ). From this group, 21 cases were additionally excluded after scrutiny of the diagnosis codes, leaving 525 incident CVE cases for analysis.
Biomarker measurements
Plate templates were designed by a researcher blind to the case/referent status of the study participants. Measurements were performed according to the manufacturer's assay protocol.
Serum IL6 and sIL6R were measured using Meso Scale Discovery Human Cytokine Assay (Gaithersburg, MD, USA). Serum samples were diluted 1:2 to measure IL6 and 1:50 to measure sIL6R levels. IL6 and sIL6R concentrations were derived from a standard curve and reported in picograms per millilitre (pg/mL) and nanograms per millilitre (ng/mL), respectively. Lower limit of detection was 0.06 pg/mL for IL6 and 0.1 ng/ mL for sIL6R.
Serum sgp130 (ng/mL) was measured using an assay development kit (#DY228) provided by R&D Systems V R (R&D systems Minneapolis, MN, USA). Serum samples were diluted 1:100 to measure sgp130. Preliminary experiments were performed to optimize the assay. A recombinant sgp130 was run as an internal control at a concentration of 5 ng/mL. A total of 96-well plates were coated with diluted capture 
antibody (4.0 lg/mL), and incubated overnight at room temperature. After blocking (2% bovine serum albumin), detection antibody (0.08 lg/ mL) and later Streptavidin and substrate colour reagent were added. Finally, the plate was read in a microplate reader (Tecan, Infinite F200) set to a wavelength of 450 nm. Sgp130 concentrations were derived from the standard curve and expressed in ng/mL. Lower limit of detection for sgp130 in our experimental condition was 1.69 ng/mL. Intra-assay variability was calculated as the average of the coefficients of variation of duplicate samples run in the same assay using the formula: coefficient of variation = duplicate standard deviation/duplicate mean. Intra-assay variability was 6.3% for IL6 (478 duplicates), 4 .7% for sIL6R (284 duplicates), and 4.5% for sgp130 (395 duplicates). Inter-assay variability was calculated as the average of coefficient of variation of duplicate samples run in 32 consecutive plates using the formula above. Interassay coefficient of variation was 3.5% for IL6, 7.5% for sIL6R, and 6.0% for sgp130. According to the manufacturer, mean intra-assay coefficient of variation should not exceed 15% and mean inter-assay 18% for both IL6 and sIL6R. For sgp130 no limits for intra-and inter-assay variability were pre-specified by the manufacturer. Previous studies have reported an intra-assay variability <10-11% and inter-assay variability <10-16%.
12,13
2.5 Derivation of molar concentration of the binary and ternary complexes IL6, sIL6R, and sgp130 interact in the circulation on a molar basis. We have calculated, for each individual the molar concentration, i.e. moles per litre (mol/L) of IL6, sIL6R, and sgp130 by dividing the serum concentration expressed in ng/mL by their respective molecular weights in kilo Dalton (kD), i.e. IL6 by 23.7 , sIL6R by 50, and sgp130 by 100. We have then estimated the nanomol/L (nmol/L) concentration of the binary and ternary complex using the formulas originally presented by Müller-Newen et al. 14, 15 ½IL6 :
We have substituted [IL6]i, [sIL6R]i, and [sgp130]i with the respective nmol/L concentrations in serum. K D1 and K D2 represent the dissociation constants for the binary and ternary complex, 0.5 and 0.05 nmol/L, respectively. 14 In additional computations, we have calculated the relative amount of the binary and ternary complex substituting K D1 and K D2 in the formula with values ten times higher and lower (Supplementary material online, Figure S2 ).
Statistical analysis
Continuous variables are presented as median and interquartile range (IQR) and binary variables as percentages. The relative risk of CVE associated with IL6, sIL6R, sgp130 serum levels, and the binary/ternary complex ratio was estimated using Cox proportional hazards models and expressed as hazard ratio (HR) with 95% confidence intervals (CIs). In the Cox models, IL6, sIL6R, sgp130, and the binary/ternary complex ratio were used as predictors, while the dependent variable in all analyses was time to the first incident CVE. First time CVE and death were censored. Schoenfeld's test did not reject proportionality of hazards.
We modelled the effect of each predictor (IL6, sIL6R, sgp130 serum levels, and the binary/ternary complex ratio) on the response variable (time to CVE) by means of natural cubic splines to allow a potential nonlinear association with the risk of CVE to be described. We used the function 'ns' in the R package 'splines' to define a spline basis with four internal knots at the empirical quantiles. IL6, sIL6R, and the binary/ternary complex ratio appeared to have a monotone association with time to the CVE. We, have therefore, included IL6 and sIL6R in the regression equation using a linear function. The risk of CVE was expressed as HR (95% CI) per unit increase in the biomarker serum levels. The natural cubic spline analysis showed that the association of sgp130 with the risk of CVE was not monotone.
To estimate the association of IL6 trans-signalling with the risk of future CVE, we have computed the ratio between the binary and ternary complex using the formula described above. The relative risk of CVE associated with increasing levels of the binary/ternary complex ratio was estimated using Cox proportional hazards models, expressed as HR with 95% CI.
In a Cox regression model with the binary/ternary complex ratio expressed as a continuous variable, the risk associated with 0.1 unit increase of the ratio was analysed. Since different values of the binary/ternary complex ratio mirror the relative excess of the binary or of the ternary complex we have chosen a cut-off value at the median (binary/ ternary complex ratio 1.59 ) based on the results obtained from the natural cubic spline analysis ( Figure 1B) . In addition, we have also further divided the binary/ternary complex ratio in three categories to estimate the risk associated with high (>60th percentile) and low (<40th percentile) binary/ternary complex ratio with the risk of CVE when compared with binary/ternary complex ratio values comprised between the 40-60th percentiles (1.57-1.60 under the assumption of K D1 = 0.5 nmol/L and K D2 = 0.05 nmol/L). These two groups represent those exposed to a relative excess of the binary complex and those exposed to a relative excess of the ternary complex, respectively. These two groups were further divided into 20 percentile subgroups (>80th percentile 1.62 and <20th percentile 1.54).
All association analyses were modelled using a crude model (model 1) and a model adjusted for the common CV risk factors: gender, hypertension (blood pressure >140/90 mmHg and/or treatment for hypertension and/or self-reported), diabetes mellitus (fasting glucose >7.0 and/or treatment for diabetes and/or self-reported), hyperlipidaemia (fasting total serum cholesterol >5.0 and/or treatment for hyperlipidaemia and/or selfreported), smoking, and body mass index (BMI) (model 2). In addition, we adjusted for treatment with drugs affecting inflammation: high dose aspirin (> _250 mg), statins, or immunomodulatory medication such as oral glucocorticoids, Sulfasalazine, Olsalazine, Mesalazine, Azathioprine, Cyclosporine, or Methotrexate. A complete-case analysis showed that differences in association between the crude and the adjusted models were not related to the presence of missing values (data not shown).
We calculated the area under the receiver operating characteristics curve (AUC) with a 95% CI and the Net Reclassification Improvement (NRI) to estimate the incremental discriminatory value of the binary/ternary complex ratio as predictor of future CVE when compared with a validated risk score, the Framingham Risk Score (FRS) in combination with IL6 using a published algorithm. 16 The FRS was categorized according to the 20% risk of a CVE in 10 years, IL6 was categorized into quartiles and the binary/ternary complex ratio was dichotomized at the median.
The statistical analyses were mainly performed using Stata Corp. (Stata statistical software: Release 14. College Station, TX, USA: StataCorp LP), natural cubic splines were analysed with R (www.r-proj ect.org) and AUC and NRI were computed using SAS version 9.4 (SAS Institute, Cary, NC, USA).
Results
The clinical characteristics of the study population at baseline are presented in Table 1 . Cases were to a lesser extent women, had higher levels of blood pressure, BMI, LDL and fasting glucose and a higher prevalence of CV risk factors. IL6, sIL6R, and sgp130 levels were higher in cases when compared with the reference population. The 525 incident CVE were recorded during a median follow-up of 16.5 (IQR 15.9-16.9) years. Of these 482 were non-fatal events: CHD requiring hospital admission (n = 159), MI (n = 158), cardiac arrest with successful resuscitation (n = 2), and 163 were due to ischaemic stroke. There were 43 fatal CVE: MI (n = 22), CHD (n = 19), cardiac arrest (n = 1), and ischaemic stroke (n = 1).
IL6 and sIL6R and the risk of future CVE
A graphical representation of the association analysis is reported in Figure 2 for IL6 (A) and for sIL6R (B). Both IL6 and sIL6R showed a monotone association with time to risk of CVE.
In the multivariable analysis, each unit (0.1 pg/mL) increase in IL6 was associated with a HR of 1.00 (95% CI 0.996-1.003), while each unit (1 ng/mL) increase in sIL6R serum levels was associated with an HR of 1.02 (95% CI 1.01-1.02).
Sgp130 and the risk of future CVE
The risk of CVE associated with sgp130 exhibited a non-monotone relationship. As shown in Figure 2C , the risk of CVE increased progressively with rising sgp130 circulating serum levels up to the 75th percentile. Sgp130 levels above the 90th percentile were associated with a progressive CV risk reduction, with the lowest risk associated with sgp130 >95th percentile.
The binary/ternary complex ratio and the risk of future CVE
Supplementary material online, Table S1 summarize the circulating concentrations of IL6, sIL6R, and sgp130 expressed as mass and molar concentrations as well as the estimated concentrations for the binary and ternary complexes expressed in nmol/L.
To investigate if and to which extent IL6 trans-signalling was associated with the risk of CVE we calculated the binary/ternary complex ratio. As shown in Figure 1B , the binary/ternary complex ratio showed a monotone association with the CVE risk. An increase of 0.1 unit in the ratio was associated with an increased CVE risk with a HR of 1.45 and 95% CI (1.28-1.64) at the crude analysis and with a HR of 1.31 and 95% CI (1.13-1.51) in the multivariable analysis (all P < 0.001). To further investigate, the association of IL6 trans-signalling with the risk of CVE estimated by circulating levels of the binary/ternary complex, we have dichotomized the ratio at the median. This cut-off was chosen upon the results of the model obtained by natural cubic splines to estimate the CVE risk in those exposed to a relative excess level of the binary/ternary complex when compared with those exposed to a relatively lower level. When compared with the reference group (<median), values of the binary/ternary complex ratio >median, representing a relative excess of the binary complex, were associated with an increased risk of CVE (adjusted HR 1.44, 95% CI 1.21-1.72) ( Table 2) . In secondary analyses, we have further analysed this association categorizing the binary/ternary complex ratio in three groups and compared the risk associated with low binary/ternary complex ratio levels (<20th and <40th percentiles) and high levels (>60th and >80th percentiles) to the reference group (40-60th percentiles). Low binary/ternary ratio values, representing a relative excess of the ternary complex, were associated with a decreased, albeit not significant, CVE risk. On the other hand, high ratio levels, representing an excess of the binary complex, were associated with a 30% increase in CVE risk: in this group, the number of cases were nearly doubled when compared with the low ratio group (Supplementary material online, Table S2) .
A similar trend in the association of the binary/ternary complex ratio with the risk of CVE was observed under the assumption of ten times higher and lower dissociation constants as shown in Supplementary material online, Figure S3 .
A small portion of study participants, approximately 4%, reported treatment with drugs affecting inflammation. Additional adjustment for treatment with any of these drugs did not change the risk estimates (data not shown).
The incremental predictive value of binary/ternary complex ratio
The addition of the binary/ternary complex ratio to FRS þ IL6 resulted in a modest increment in the AUC: FRS þ IL6 þ binary/ternary complex 
Discussion
The main finding of this study is that IL6 trans-signalling, estimated by the binary/ternary complex ratio, is associated with an increased risk of future CVE. To the best of our knowledge, this is the first prospective study analysing the association of IL6 trans-signalling with the risk of future CVE. IL6 and its soluble receptors, sIL6R and sgp130 constitute the components of the IL6 trans-signalling system. To promote pro-inflammatory effects, IL6 must bind sIL6R to form the binary complex. Once formed the binary complex can either bind gp130 to elicit an intracellular signal or is, due to the high affinity of sgp130, rapidly neutralized through the formation of the inactive ternary complex ( Figure 1A) . Thus, to analyse the effect of IL6 trans-signalling on the risk of future CVE it is important to estimate the proportion between the binary and ternary complexes. Previous studies on IL6 trans-signalling have focused on analysing the association of the mass concentration of the individual moieties with CVE risk. However, experimental studies have shown that both IL6 and sIL6R and IL6:sIL6R and sgp130 interact on a molar basis in the circulation to form the binary and ternary complexes. 17 Moreover, a concentration gradient exists among these three molecular entities: sIL6R circulates in molar excess when compared with IL6 and sgp130 circulates in molar excess when compared with IL6:sIL6R. The gradient keeps the majority of IL6 molecules in the circulation bound in binary and ternary complexes. In inflammatory conditions, however, the relative excess of sIL6R increases, drives the formation of the binary complex and perpetuates IL6 trans-signalling. Therefore, the level of IL6 trans-signalling depends on the concentration of sIL6R and on the neutralizing capacity of sgp130. 14, 18 For this reason, we have first assessed the association of IL6, sIL6R, and sgp130 with the risk of CVE and then, based on what is known from experimental studies of the biology of IL6 trans-signalling, we have made an attempt to estimate how the level of the activity of the IL6 transsignalling, measured by the ratio between the binary and ternary complex was associated with the risk of CVE.
Our results show that increasing circulating levels of IL6 and sIL6R exhibit a monotone association with the risk of CVE. This is consistent with the observation that increased circulating levels of IL6 are associated with an increased risk of CVE 7 and with the results of observational studies demonstrating a detrimental role of high circulating sIL6R levels in the acute phase of MI. 8, [19] [20] [21] In particular, high sIL6R levels at the time of MI 19, 21 have been associated with a higher degree of myocardial injury 19 and with a reduced myocardial reperfusion after percutaneous coronary intervention. 20 More recently, high circulating sIL6R levels were shown to be associated with MI risk in a large MI case control study 9 and with an increased risk of all cause and CV mortality in patients with STelevation MI. 8 Of importance, sIL6R circulating levels are genetically determined and Mendelian randomization experiments have indicated that IL6R is causally related to CHD. 22, 23 We also observed a decreased CVE risk associated with very high levels of sgp130. Observational studies analysing the association of sgp130 with the risk of CVE have shown that high circulating sgp130 were associated with the risk of adverse events in MI patients, 8 with all-cause and CV mortality in elderly patients with heart failure on ischaemic basis 24 and with prevalent metabolic syndrome, biomarkers of endothelial dysfunction and arterial stiffness in elderly men. 10 On the other hand, it was recently shown that symptomatic CHD patients where coronary angiography demonstrated coronary stenosis had lower sgp130 plasma levels when compared with subjects with intact arteries and that sgp130 was inversely correlated with the number of coronary arteries affected. 25 Moreover, we have previously reported a protective effect of high sgp130 towards the occurrence of MI. 9 In particular, we observed that low levels of sgp130 could explain 19% of the risk of MI associated with high circulating sIL6R. It is tempting to speculate that extreme derangements in circulating sgp130 levels are necessary to observe changes in the individual CV risk profile and to exert a favourable effect on the atherogenic process.
In the light of our current findings we can speculate that, given the fine tuning of IL6 trans-signalling, the analysis of the association of each one of the three biomarkers with the risk of future CVE may give different results depending on the relative amount of IL6, sIL6R, and sgp130 in the circulation, the stage of the disease as well as differences in study populations.
To partly overcome these limitations, we have derived the concentration of circulating binary and ternary complexes and estimated the association of the binary/ternary complex as a measure of the IL6 transsignalling. Our results show a monotone association of increasing levels of the binary/ternary complex ratio with CVE risk, mirroring increasing relative excess of the binary complex, and risk of future CVE. In addition, we have also observed that the binary/ternary complex slightly improves the ability to predict CVE when compared with the FRS and IL6, in line with the effect size observed for other CV biomarkers. 26 IL6 was chosen as reference biomarker since it is a known CV risk predictor 7 and regulates IL6 classical and trans-signalling, as opposed to CRP that is a marker only for IL6 classical signalling. The interpretation of the performance of a biomarker in the setting of prediction is more complex than in the diagnostic setting and depends on multiple factors such as cost of the additional biomarker and its clinical utility. 27 The fact that the IL6R is causally related to CHD and that the binary/ternary complex ratio could represent a novel biomarker to be used in clinical practice to monitor the efficacy of anti-inflammatory treatments targeting the IL1b-IL6-CRP pathway ( Figure 3 ) adds relevance to our finding. 28 The results of the Cantos trial indicate that targeting the inflammatory IL1b-IL6-CRP pathway is appropriate when aiming at preventing CVE. 5 Being the inhibitor of IL1b, Canakinumab targets not only IL6 transsignalling but also IL6 classical signalling as indicated by the decrease in CRP, thus affecting important IL6 physiological functions above all in the immune system and increasing the risk for serious infections. 29 In this perspective, our results suggest that treatment with the recombinant sgp130 might represent a suitable therapeutical approach since it would increase the proportion of ternary complex in the circulation thus reducing the detrimental effect of excessive IL6 trans-signalling without affecting the IL6 classical signalling (Figure 3) . Data from an experimental animal model of atherosclerosis support the hypothesis that treatment with sgp130 prevents atherosclerotic plaques progression 6 and novel findings suggest the treatment with recombinant sgp130 might be effective in low grade inflammatory disease such as atherosclerosis. 30 An on-going clinical trial in patients affected by Crohn's disease, might provide some preliminary information on the efficacy of treatment with recombinant sgp130 in chronic inflammatory diseases. 31 Our study has several limitations. The study provides no evidence on the mechanisms underlying the observed association, since it is an observational study. However, the hypothesis tested in our study, i.e. that IL6 trans-signalling estimated by the binary/ternary complex ratio is associated with CVE risk, stems from experimental evidence linking the IL6 trans-signalling to atherosclerosis progression. 3 In this perspective, our study takes the knowledge acquired further, from the bench to a population-based study. Sgp130 exists in at least three isoforms with different molecular weights and the assay used in the present study does not discriminate between these isoforms. A rare 50kD isoform also known as sgp130-RAPS has only been detected in patients affected by rheumatoid arthritis; an isoform known as sgp130-E10 represents about 1-2% of the circulating sgp130 and the most common isoform has a molecular weight of 90-110 kD. 32 We have calculated sgp130 molar concentration assuming a molecular weight of 100 kD, as previously reported. 14 Similarly, the assay used to measure IL6 and sIL6R does not discriminate between free and bound molecules. Nonetheless, as we have analysed all the study participants at baseline and prevalent cases were excluded, we might assume that eventual differences in the proportion of free and bound IL6 as well as differences in stability of the binary and ternary complexes in the circulation are equally distributed in our study population. The formula used in the main analysis to estimate the binary and ternary complex concentrations has been derived in in vitro studies. However, we have performed the association analysis assuming 10 times higher as well as 10 times lower dissociation constants for both the binary and the ternary complex obtaining comparable results. Moreover, we could not stratify our study population according to the presence of prevalent chronic inflammatory diseases that are associated with high circulating sIL6R levels, due to the limited information present in our data. However, we have adjusted for immunomodulatory drugs, which can be seen as proxys for chronic inflammatory disease. All the data on medications and comorbidities were obtained through the questionnaire and the medical examination at baseline. Since the study participants were not contacted again during the follow up and the outcome in the present study is retrieved from the national patient registry, we did not have information on incident comorbidities and changes in eventual medical treatment during the follow up and could not account for them in the association analysis.
Similarly, we cannot exclude that IL6, sIL6R, and sgp130 levels in the circulation change over time since we have not measured IL6 and the soluble receptors at more than one time point. The major strength of our study is that it is the first prospective cohort study investigating the functional moieties of IL6 trans-signalling as potential risk markers of future CVE. Due to the unique Swedish personal identification numbers and linkage to the mandatory national registries we have a 100% follow up. 33 In conclusion, our results indicate that IL6 trans-signalling, measured by the relative excess of the binary IL6:sIL6R complex, is associated with an increased risk of CVE. Further studies are needed to define the role of IL6 trans-signalling as a potential target for treatment and prevention of CVE.
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